Cargando…

An exploratory study of CT-guided percutaneous radiofrequency ablation for stage I thymoma

BACKGROUND: Thymoma is a rare tumor that originates from thymic epithelial cells and is usually associated with myasthenia gravis. Radiofrequency ablation (RFA) is a minimally invasive and curative treatment for other tumors, but RFA has not been used for the early treatment of thymoma. METHODS: The...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Jun, Yuan, Shaofei, Chang, Boyang, Huang, Jinsheng, Geng, Xiaojing, Cai, Xiuyu, Hu, Pili, Zhang, Bei, Xia, Liangping, Wu, Peihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889348/
https://www.ncbi.nlm.nih.gov/pubmed/31791411
http://dx.doi.org/10.1186/s40644-019-0267-8
_version_ 1783475397308973056
author Dong, Jun
Yuan, Shaofei
Chang, Boyang
Huang, Jinsheng
Geng, Xiaojing
Cai, Xiuyu
Hu, Pili
Zhang, Bei
Xia, Liangping
Wu, Peihong
author_facet Dong, Jun
Yuan, Shaofei
Chang, Boyang
Huang, Jinsheng
Geng, Xiaojing
Cai, Xiuyu
Hu, Pili
Zhang, Bei
Xia, Liangping
Wu, Peihong
author_sort Dong, Jun
collection PubMed
description BACKGROUND: Thymoma is a rare tumor that originates from thymic epithelial cells and is usually associated with myasthenia gravis. Radiofrequency ablation (RFA) is a minimally invasive and curative treatment for other tumors, but RFA has not been used for the early treatment of thymoma. METHODS: The current study included 13 patients with stage I thymoma who were not candidates for surgical resection or video-assisted thoracoscopic surgery (VATS). All patients underwent first-line CT-guided percutaneous RFA. The feasibility and therapeutic effects of the intervention were thoroughly documented. RESULTS: All tumors were completely ablated (13 / 13, 100%). During follow-up (median 80.5 months, range, 64.6–116.9 months), only 1 of the 13 patients had recurrence of thymoma (1 / 13, 7.7%) at 35.5 months after the initial ablation. There were no surgery-related deaths after RFA treatment. The most common complications were fever (13 / 13, 100%) and pain (13 / 13, 100%). There was only one patient who occurred severe puncture-related bleeding during the procedure that needed blood transfusion and intravascular embolization of the punctured-injured vessel. CONCLUSION: CT-guided percutaneous RFA for treatment of stage I thymoma is associated with minor trauma, few complications and good treatment outcomes.
format Online
Article
Text
id pubmed-6889348
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-68893482019-12-11 An exploratory study of CT-guided percutaneous radiofrequency ablation for stage I thymoma Dong, Jun Yuan, Shaofei Chang, Boyang Huang, Jinsheng Geng, Xiaojing Cai, Xiuyu Hu, Pili Zhang, Bei Xia, Liangping Wu, Peihong Cancer Imaging Research Article BACKGROUND: Thymoma is a rare tumor that originates from thymic epithelial cells and is usually associated with myasthenia gravis. Radiofrequency ablation (RFA) is a minimally invasive and curative treatment for other tumors, but RFA has not been used for the early treatment of thymoma. METHODS: The current study included 13 patients with stage I thymoma who were not candidates for surgical resection or video-assisted thoracoscopic surgery (VATS). All patients underwent first-line CT-guided percutaneous RFA. The feasibility and therapeutic effects of the intervention were thoroughly documented. RESULTS: All tumors were completely ablated (13 / 13, 100%). During follow-up (median 80.5 months, range, 64.6–116.9 months), only 1 of the 13 patients had recurrence of thymoma (1 / 13, 7.7%) at 35.5 months after the initial ablation. There were no surgery-related deaths after RFA treatment. The most common complications were fever (13 / 13, 100%) and pain (13 / 13, 100%). There was only one patient who occurred severe puncture-related bleeding during the procedure that needed blood transfusion and intravascular embolization of the punctured-injured vessel. CONCLUSION: CT-guided percutaneous RFA for treatment of stage I thymoma is associated with minor trauma, few complications and good treatment outcomes. BioMed Central 2019-12-02 /pmc/articles/PMC6889348/ /pubmed/31791411 http://dx.doi.org/10.1186/s40644-019-0267-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Dong, Jun
Yuan, Shaofei
Chang, Boyang
Huang, Jinsheng
Geng, Xiaojing
Cai, Xiuyu
Hu, Pili
Zhang, Bei
Xia, Liangping
Wu, Peihong
An exploratory study of CT-guided percutaneous radiofrequency ablation for stage I thymoma
title An exploratory study of CT-guided percutaneous radiofrequency ablation for stage I thymoma
title_full An exploratory study of CT-guided percutaneous radiofrequency ablation for stage I thymoma
title_fullStr An exploratory study of CT-guided percutaneous radiofrequency ablation for stage I thymoma
title_full_unstemmed An exploratory study of CT-guided percutaneous radiofrequency ablation for stage I thymoma
title_short An exploratory study of CT-guided percutaneous radiofrequency ablation for stage I thymoma
title_sort exploratory study of ct-guided percutaneous radiofrequency ablation for stage i thymoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889348/
https://www.ncbi.nlm.nih.gov/pubmed/31791411
http://dx.doi.org/10.1186/s40644-019-0267-8
work_keys_str_mv AT dongjun anexploratorystudyofctguidedpercutaneousradiofrequencyablationforstageithymoma
AT yuanshaofei anexploratorystudyofctguidedpercutaneousradiofrequencyablationforstageithymoma
AT changboyang anexploratorystudyofctguidedpercutaneousradiofrequencyablationforstageithymoma
AT huangjinsheng anexploratorystudyofctguidedpercutaneousradiofrequencyablationforstageithymoma
AT gengxiaojing anexploratorystudyofctguidedpercutaneousradiofrequencyablationforstageithymoma
AT caixiuyu anexploratorystudyofctguidedpercutaneousradiofrequencyablationforstageithymoma
AT hupili anexploratorystudyofctguidedpercutaneousradiofrequencyablationforstageithymoma
AT zhangbei anexploratorystudyofctguidedpercutaneousradiofrequencyablationforstageithymoma
AT xialiangping anexploratorystudyofctguidedpercutaneousradiofrequencyablationforstageithymoma
AT wupeihong anexploratorystudyofctguidedpercutaneousradiofrequencyablationforstageithymoma
AT dongjun exploratorystudyofctguidedpercutaneousradiofrequencyablationforstageithymoma
AT yuanshaofei exploratorystudyofctguidedpercutaneousradiofrequencyablationforstageithymoma
AT changboyang exploratorystudyofctguidedpercutaneousradiofrequencyablationforstageithymoma
AT huangjinsheng exploratorystudyofctguidedpercutaneousradiofrequencyablationforstageithymoma
AT gengxiaojing exploratorystudyofctguidedpercutaneousradiofrequencyablationforstageithymoma
AT caixiuyu exploratorystudyofctguidedpercutaneousradiofrequencyablationforstageithymoma
AT hupili exploratorystudyofctguidedpercutaneousradiofrequencyablationforstageithymoma
AT zhangbei exploratorystudyofctguidedpercutaneousradiofrequencyablationforstageithymoma
AT xialiangping exploratorystudyofctguidedpercutaneousradiofrequencyablationforstageithymoma
AT wupeihong exploratorystudyofctguidedpercutaneousradiofrequencyablationforstageithymoma